The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(100)

Community oncology’s growing role in the future of cancer care (Sponsored)

Community oncology’s growing role in the future of cancer care (Sponsored)

Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patients treated outside large academic medical centers. ...

9 Feb 15min

The biggest potential drug launches of 2026

The biggest potential drug launches of 2026

The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual report on the biggest potential launches of 2026 details how the next obesity med...

6 Feb 13min

How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)

How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)

Please see the following USPI, US ISI, EU SmPC and Canadian Product Monograph for complete LIVMARLI product information: US Important Safety Information (https://livmarli.com/important-safety-informat...

3 Feb 14min

Why human expertise still matters in AI-driven med comms (Sponsored)

Why human expertise still matters in AI-driven med comms (Sponsored)

Artificial intelligence is reshaping medical communications, but it is not a substitute for human judgment. In this episode of The Top Line, experts from RTI Health Solutions explore how AI is being u...

2 Feb 20min

Biopharma's rebound keeping pace so far

Biopharma's rebound keeping pace so far

In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry watchers predicted in the closing months of 2025. Fierce Ph...

30 Jan 22min

JPM26: Sunshine, AI and the deals that weren't

JPM26: Sunshine, AI and the deals that weren't

With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025 as it heads into what is sure to be another ev...

23 Jan 16min

From approval to value: Why evidence storytelling now matters (Sponsored)

From approval to value: Why evidence storytelling now matters (Sponsored)

As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear evidence storytelling drives access decisions.See omnystu...

19 Jan 17min

Drug approvals went from crawl to sprint in 2025

Drug approvals went from crawl to sprint in 2025

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications. By the end of the ...

16 Jan 13min

Populært innen Politikk og nyheter

giver-og-gjengen-vg
aftenpodden
forklart
stopp-verden
aftenpodden-usa
popradet
fotballpodden-2
det-store-bildet
dine-penger-pengeradet
rss-gukild-johaug
rss-espen-lee-usensurert
hanna-de-heldige
nokon-ma-ga
rss-penger-polser-og-politikk
rss-ness
aftenbla-bla
bt-dokumentar-2
frokostshowet-pa-p5
e24-podden
ta-dokumentar